Cardiovascular Risk in Patients with Primary Hyperparathyroidism

Author(s): Symeon Tournis*, Konstantinos Makris, Etienne Cavalier, George Trovas

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 43 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Primary hyperparathyroidism (PHPT) is one of the most common endocrine disorders characterized by parathyroid hormone (PTH)-dependent hypercalcemia. Cardinal features include low trauma fractures, nephrolithiasis, and chronic kidney disease. Several experimental studies established that parathyroid hormone exerts actions on the cardiovascular (CV) system, including vasodilatation and positive inotropic and chronotropic effects. Observational studies, especially in severe cases, report a higher prevalence of hypertension, diabetes mellitus, lipid abnormalities, endothelial dysfunction, arrhythmias, and left ventricular hypertrophy in patients with PHPT, while the risk of CV events seems to be increased in severe cases. However, the effect of surgery is inconsistent on CV abnormalities and, more importantly, on CV disease (CVD) events, especially in mild cases. In the current review, we describe the available evidence linking PHPT and CVD, as well as the effect of surgical management and pharmacological treatment on CVD manifestations in patients with PHPT. Based on the current evidence, CVD is not considered an indication for surgery.

Keywords: Primary hyperparathyroidism, cardiovascular disease, calcium, parathyroid hormone, hypertension, parathyroidectomy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 43
Year: 2020
Published on: 22 December, 2020
Page: [5628 - 5636]
Pages: 9
DOI: 10.2174/1381612824999201105165642
Price: $65

Article Metrics

PDF: 20